Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lupus Foundation of America (LFA) has welcomed the results of a new long-term study for the treatment of lupus nephritis (lupus-related kidney disease) which demonstrated superiority of CellCept (mycophenolate mofetil or MMF) to azathioprine (standard care) as a long-term treatment for lupus nephritis.
Subscribe to our email newsletter
Reportedly, the Phase III study results released by Vifor Pharma and Roche reached the primary endpoint of delaying treatment failure in patients with lupus nephritis who had successfully responded to induction therapy and were in remission.
Sandra Raymond, president and CEO of the Lupus Foundation of America, stated that the results of this study provide more good news for the estimated 1.5 million Americans and the more than five million people worldwide who are living with lupus.
He added that the previous studies have provided convincing evidence that CellCept is better tolerated, and, more importantly to patients and their doctors, is associated with few serious or life-threatening infections and hospitalizations. We are greatly encouraged that people with lupus nephritis and their physicians will have additional options available to treat this potentially life-threatening and disabling complication of lupus.